Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension.

Nathane Santanna FelixLucas de MendonçaCassia Lisboa BragaJaqueline Soares da SilvaCynthia Dos Santos SamaryJuliana Borges VieiraFernanda CruzNazareth de Novaes RochaGisele Zapata-SudoPatricia Rieken Macedo RoccoPedro Leme Silva

Published in: British journal of pharmacology (2019)

In this model of monocrotaline-induced PAH, the combination of the new inhibitor of FGF receptor-1, infigratinib, and sildenafil effectively improved haemodynamics and decreased vascular remodelling.

Keyphrases

pulmonary arterial hypertension
pulmonary hypertension
pulmonary artery
high glucose
diabetic rats
binding protein
oxidative stress
drug induced
endothelial cells
coronary artery